TARA · Categories · Form 4

TARA - SEC Form 4 insider transactions

Protara Therapeutics Inc. (TARA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for TARA

• 17d
  SEC Form 4 filed by Zummo Jacqueline

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 24d
  SEC Form 4 filed by Zummo Jacqueline

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 89d
  Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 89d
  VP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 89d
  CEO and President Shefferman Jesse covered exercise/tax liability with 8,732 shares, decreasing direct ownership by 0.85% to 1,021,832 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 89d
  Chf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 3,724 shares, decreasing direct ownership by 3% to 118,559 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 94d
  CEO and President Shefferman Jesse covered exercise/tax liability with 16,322 shares, decreasing direct ownership by 2% to 1,030,564 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 94d
  Chf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 6,578 shares, decreasing direct ownership by 5% to 122,283 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 94d
  Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,063 shares, decreasing direct ownership by 4% to 67,376 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 94d
  VP, Controller Fry Hannah covered exercise/tax liability with 2,132 shares, decreasing direct ownership by 5% to 44,180 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  Chief Commercial Officer Conkling William was granted 26,000 shares, increasing direct ownership by 52% to 76,000 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  Chief Financial Officer Fabbio Patrick was granted 28,000 shares, increasing direct ownership by 66% to 70,439 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  VP, Controller Fry Hannah was granted 9,500 shares, increasing direct ownership by 26% to 46,312 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  Chief Medical Officer Nicacio Leonardo Viana was granted 26,000 shares, increasing direct ownership by 50% to 78,181 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  CEO and President Shefferman Jesse was granted 87,000 shares, increasing direct ownership by 9% to 1,046,886 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 95d
  Chf Scientific Operations Off Zummo Jacqueline was granted 30,000 shares, increasing direct ownership by 30% to 128,861 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 293d
  CEO and President Shefferman Jesse gifted 300,000 shares (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 300d
  CEO and President Shefferman Jesse gifted 18,667 shares, decreasing direct ownership by 2% to 959,886 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Sargen Gregory

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Levy Richard S

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Flannelly Barry P

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Solomon Michael Edward

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Smith Cynthia

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Huang Jane

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Garceau Roger

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 317d
  SEC Form 4 filed by Director Beshar Luke M

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 326d
  Chief Commercial Officer Conkling William was granted 50,000 shares (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 374d
  Chief Medical Officer Nicacio Leonardo Viana was granted 50,000 shares, increasing direct ownership by 2,293% to 52,181 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 394d
  Chf Scientific Operations Off Zummo Jacqueline sold $96,145 worth of shares (21,224 units at $4.53), decreasing direct ownership by 18% to 98,861 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 394d
  Amendment: SEC Form 4 filed by Chief Financial Officer Fabbio Patrick

  4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 394d
  Amendment: SEC Form 4 filed by VP, Controller Fry Hannah

  4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 394d
  Amendment: SEC Form 4 filed by CEO and President Shefferman Jesse

  4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 394d
  Amendment: SEC Form 4 filed by Chf Scientific Operations Off Zummo Jacqueline

  4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 453d
  CEO and President Shefferman Jesse was granted 65,000 shares, increasing direct ownership by 7% to 994,022 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 453d
  Chf Scientific Operations Off Zummo Jacqueline was granted 24,500 shares, increasing direct ownership by 24% to 126,639 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 453d
  VP, Controller Fry Hannah was granted 9,500 shares, increasing direct ownership by 32% to 38,942 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 453d
  Chief Financial Officer Fabbio Patrick was granted 23,500 shares, increasing direct ownership by 107% to 45,500 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 458d
  CEO and President Shefferman Jesse covered exercise/tax liability with 15,469 shares, decreasing direct ownership by 2% to 913,553 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 458d
  Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,061 shares, decreasing direct ownership by 14% to 18,939 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 458d
  VP, Controller Fry Hannah covered exercise/tax liability with 2,130 shares, decreasing direct ownership by 7% to 27,312 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 458d
  Chf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 6,554 shares, decreasing direct ownership by 6% to 95,585 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 474d
  CEO and President Shefferman Jesse covered exercise/tax liability with 6,479 shares, decreasing direct ownership by 0.69% to 929,022 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 474d
  Chf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 2,157 shares, decreasing direct ownership by 2% to 102,139 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 474d
  VP, Controller Fry Hannah covered exercise/tax liability with 394 shares, decreasing direct ownership by 1% to 29,442 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 591d
  Large owner Opaleye Management Inc. sold $271,715 worth of shares (158,901 units at $1.71) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 593d
  Large owner Opaleye Management Inc. sold $114,251 worth of shares (61,992 units at $1.84) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 604d
  CEO and President Shefferman Jesse gifted 8,563 shares, decreasing direct ownership by 0.91% to 935,501 units (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 647d
  Large owner Opaleye Management Inc. sold $27,828 worth of shares (11,396 units at $2.44) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 654d
  Large owner Opaleye Management Inc. sold $175,842 worth of shares (74,551 units at $2.36) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 662d
  Large owner Opaleye Management Inc. sold $17,598 worth of shares (8,288 units at $2.12) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 667d
  Large owner Opaleye Management Inc. sold $142,503 worth of shares (64,568 units at $2.21) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 668d
  Large owner Opaleye Management Inc. sold $28,734 worth of shares (12,725 units at $2.26) (SEC Form 4)

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Smith Cynthia

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Solomon Michael Edward

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Flannelly Barry P

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Beshar Luke M

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Garceau Roger

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Levy Richard S

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Sargen Gregory

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
• 685d
  SEC Form 4 filed by Director Huang Jane

  4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

Other TARA categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends